M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, vol.448, issue.7153, pp.561-567, 2007.

A. T. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crino et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, issue.25, pp.2385-94, 2013.

T. Hida, H. Nokihara, M. Kondo, Y. H. Kim, K. Azuma et al., Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, vol.390, pp.29-39, 2017.

S. Peters, D. R. Camidge, A. T. Shaw, S. Gadgeel, J. S. Ahn et al., Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer, N Engl J Med, vol.377, issue.9, pp.829-867, 2017.

J. Soria, D. Tan, R. Chiari, Y. Wu, L. Paz-ares et al., First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, vol.389, pp.917-946, 2017.

D. R. Camidge, H. R. Kim, M. Ahn, J. Yang, J. Han et al., Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer, N Engl J Med, vol.379, issue.21, pp.2027-2066, 2018.

H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. Mcdonnell et al., An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms, Cancer Res, vol.67, issue.9, pp.4408-4425, 2007.

N. Hanna, D. Johnson, S. Temin, S. J. Baker, J. Brahmer et al., Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update, J Clin Oncol, vol.35, issue.30, pp.3484-515, 2017.

B. J. Solomon, B. Besse, and T. M. Bauer, Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study, Lancet Oncol, vol.19, pp.1654-67, 2018.

R. M. Huber, K. H. Hansen, P. Rodríguez, L. West, and H. L. , Brigatinib in Crizotinib-refractory ALK+ non-small cell lung Cancer: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial, J Thorac Oncol, 2019.

F. Cappuzzo, D. Moro-sibilot, O. Gautschi, E. Boleti, E. Felip et al., Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus, Lung Cancer, vol.87, issue.2, pp.89-95, 2015.

N. Srivastava, P. A. Vanderlaan, C. P. Kelly, and D. B. Costa, Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer, J Thorac Oncol, vol.8, issue.3, pp.23-27, 2013.

J. M. Pacheco, D. Gao, D. Smith, T. Purcell, M. Hancock et al., Natural history and factors associated with overall survival in stage IV ALKrearranged non-small cell lung Cancer, J Thorac Oncol, vol.14, issue.4, pp.691-700, 2019.

K. L. Johung, N. Yeh, N. B. Desai, T. M. Williams, T. Lautenschlaeger et al., Extended survival and prognostic factors for patients with ALKrearranged non-small-cell lung Cancer and brain metastasis, J Clin Oncol, vol.34, issue.2, pp.123-132, 2016.

D. F. Halpenny, S. Mcevoy, A. Li, S. Hayan, M. Capanu et al., Renal cyst formation in patients treated with crizotinib for non-small cell lung cancerincidence, radiological features and clinical characteristics, Lung Cancer, vol.106, pp.33-39, 2017.

H. Ishida, W. Ichikawa, and Y. Sasaki, Crizotinib-induced pancreatic pseudocyst: a novel adverse event, BMJ Case Rep, p.2015211556, 2015.

A. F. Nifosì, M. Zuccarello, L. Nifosì, H. Saus, V. Nifosì et al., Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology, J Korean Assoc Oral Maxillofac Surg, vol.45, issue.1, pp.3-8, 2019.

A. Anesi, L. Generali, L. Sandoni, S. Pozzi, and A. Grande, From osteoclast differentiation to osteonecrosis of the jaw: molecular and clinical insights, Int J Mol Sci, vol.20, issue.19, p.4925, 2019.